Janssen Research & Development

A division of Janssen Pharmaceutica NV

Turnhoutseweg 30

B-2340 Beerse

BELGIUM

 

janssenpharmaceutica.be

 

Project leader

 
Pieter J. Peeters, PhD

Senior Director, Integrative Systems Biology
Community of Research Excellence & Advanced Technology
C.R.E.A.Te

StemBANCC WP05 Co-lead

Phone +32 14 606648
Fax +32 14 605737
E-Mail  

Project staff

 
Frank Jacobs
 
Phone +32 14 606572
E-Mail  

 

 
Miroslav Cik
 
Phone +32 14 603874 
E-Mail  

 

 
Kurt Van Baelen, PhD
Principal Scientist, Integrative Systems Biology                               
Community of Research Excellence & Advanced
Technology
CREATe
Phone +32 14 606612
E-Mail  

 

 
Marianne Tuefferd
 
E-Mail  

 

 
Ines Royaux
 StemBANCC WP04 Co-lead
Phone +32 14 605765
E-Mail  

 

 
Hua Rong Lu
 
E-Mail  

 

 
Rony Nuydens
 
E-Mail  

Institute presentation

Janssen Research & Development brings together the capabilities, culture and people representing our legacy organizations in virology, small molecules and biotechnology. We share an overarching mission: to address and solve the most important unmet medical needs of our time. As Janssen R&D, we work together to harness our combined knowledge and resources, leverage the power and promise of outstanding science, and enhance the length and quality of life for people throughout the world.

 

More than a half century ago, Dr. Paul Janssen established Janssen Pharmaceutica, N.V., a pharmaceutical research laboratory based in Beerse, Belgium. Dr. Paul, as he was known throughout the global scientific community, was a gifted and passionate scientist who refused to accept that there are limits to science and had an unceasing willingness to consider new approaches.

 

Janssen Pharmaceutica became part of the Johnson & Johnson family of companies in 1961. In time, other innovative companies led by other brilliant researchers and entrepreneurs joined the Johnson & Johnson family of companies: in 1999, Johnson & Johnson acquired, Centocor, Inc. (now known as Janssen Biotech, Inc.), a leader in monoclonal antibody technology and acute vascular care and immunology products, in one of the largest biotech deals at the time and in 2002, Tibotec, Inc., a company dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases, joined the Johnson & Johnson family of companies. The spirit of innovation, and the belief that science done well can benefit humanity, has been an integral part of the last 50 years of pharmaceuticals within the Johnson & Johnson family of companies and continues to live on at the Janssen companies.

 

Today, we have thousands of committed employees in many innovative companies located around the world. We are focused on developing novel treatments in five major therapeutic areas: neuroscience, infectious diseases and vaccines, oncology, immunology and cardiovascular/metabolism.

 

Contributing to this project will be especially the departments CREATe, Neuroscience Discovery and Tox/Path located amongst others in Beerse Belgium. The contribution will mainly be to the neuroscience and dug safety related work packages. Pieter Peeters is co-lead for the molecular profiling work package.